Take­da hops on­to $61M round for CRISPR play­er syn­the­siz­ing Cas9 al­ter­na­tives

Take­da Ven­tures and Or­biMed have helped pump $61 mil­lion in­to a New York biotech join­ing the rush to dra­mat­i­cal­ly ex­pand the CRISPR tool kit.

One cru­cial com­po­nent in the CRISPR gene edit­ing process is a nu­cle­ase that cuts the tar­get DNA once it’s led there by a guide RNA. Cas9 is the most well known and broad­ly used among them, al­though re­searchers have been com­ing up with a va­ri­ety of al­ter­na­tives. The one that Emen­do Bio­ther­a­peu­tics will be ad­vanc­ing with its new fund­ing is dubbed OM­NI.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.